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Background: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study
was to survey the natural history of bone metastasis in CRC.
Patients and methods: This retrospective, multicenter, observational study of 264 patients with CRC involving bone
examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency,
zoledronic acid therapy, and disease outcomes.
Results: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most
common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from
CRC diagnosis to bone metastases was 11.00 months; median time to ﬁrst SRE thereafter was 2.00 months. Radiation
and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs.
Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not signiﬁcantly affect survival.
Subgroup analyses revealed that zoledronic acid signiﬁcantly prolonged median time to ﬁrst SRE (2.00 months versus
1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.
Conclusion: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in
this setting.
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introduction
Colorectal cancer (CRC) is among the three most common
cancers, with an estimated 1.2 million new cases diagnosed
worldwide per year [1]. Although CRC is generally more
aggressive than breast cancer, mortality rates are notably
lower than for other solid tumors such as lung cancer [2].
Before the introduction of modern chemotherapy and
targeted treatment options, bone metastases were reported in
∼10% to 24% based on clinical and autopsy records of
patients with advanced CRC (N = 118), and affected patients
had limited survival [3]. More recently, a retrospective
analysis of 252 patients with colon cancer showed that 5.5%
(n = 14) of patients had bone metastases at primary
diagnosis [4]. Patients with metastatic CRC are now typically
treated with 5-ﬂuorouracil and leucovorin and either
oxaliplatin or irinotecan (FOLFOX or FOLFIRI), and the
anti-vascular endothelial growth factor antibody bevacizumab
or the anti-epidermal growth factor receptor antibodies
cetuximab or panitumumab are added to these regimens
when indicated [5–10].
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With the newer treatment regimens, median survival of >20
months has been reported for patients with advanced CRC
[5–10]. However, the increase in overall survival in patients
with metastatic cancer increases the likelihood that patients
have the time to not only develop bone metastases during the
course of their disease but also that the associated bone
destruction will manifest within the patient’s lifetime, resulting
in potentially debilitating sequelae. The acute consequences of
bone metastases include skeletal-related events (SREs; deﬁned
as pathological fracture, the need for radiotherapy or surgery to
bone, spinal cord compression, and hypercalcemia of
malignancy) that may undermine patients’ function and
quality of life [11]. These SREs have been correlated with
signiﬁcant decrements in quality of life and reduced survival
[11]. However, despite the potentially devastating implications
of bone metastases, there are limited data in the literature
about the natural history of bone metastasis in patients with
CRC [4, 11–16]. Here, we report the ﬁnal data of a large Italian
multicenter study on the natural history of patients with bone
metastases from CRC.
methods
study design
This was a retrospective, observational multicenter study of medical records
for patients treated at 16 oncology centers in Italy, who were diagnosed
with CRC between November 1985 and May 2009. Data were collected
from patients of all ages who received any standard treatment (i.e. not an
experimental protocol or trial). All patients had been treated and followed
according to the usual practice of their physicians. Only patients with CRC
who had at least one bone metastasis during their disease course and who
had died of CRC itself or disease-related complications before the start of
the study were included. Patients were deﬁned as having bone metastasis if
two or more of the following criteria were satisﬁed: (i) physician reported
patient as having bone metastasis; (ii) at least one bone metastasis
identiﬁed via a positive bone scan; (iii) record of palliative radiation
therapy to bone; or (iv) identiﬁcation of bone metastasis by another
assessment, such as standard X-rays, computed tomography (CT) scans, or
magnetic resonance imagings of the skeleton.
Data were collected throughout the disease course for all cancer
treatments, including surgery, radiation therapy, chemotherapy, and
biological therapies. Variables assessed for prognostic correlations included
gender, age, primary site, histotype, stage at diagnosis of primary cancer,
tumor grade, adjuvant chemotherapy, time to appearance of visceral
metastases, number of sites of visceral metastases, number and sites of
bone metastases, time to appearance of bone metastases, presence of bone
pain, times to ﬁrst and subsequent SREs (from diagnosis of bone
metastasis), SRE types, survival after ﬁrst SRE, and type and times of
bisphosphonate therapy.
statistical analysis
In the univariate model, all the clinical variables were evaluated as
predictors for shorter time to bone metastasis, higher risk of skeletal
morbidity (i.e. SRE), and shorter time from SRE to death. Patients who did
not have a recorded date for a speciﬁc event were censored at the date of
death. All survival intervals were determined by the Kaplan–Meier
product-limit method [17]. The differences in survival according to clinical
parameters or treatment were evaluated by the log-rank test [18] and
described by the Kaplan–Meier method. Finally, the Cox proportional
hazards model was applied to the multivariate survival analysis. All the
signiﬁcant variables in the univariate model were used to build the
multivariate model of survival, and median values were derived from
whole-month values rather than fractions. Patients included in the analysis
were diagnosed with bone metastases after September 1988 and died before
July 2009. SPSS software (version 17.00; SPSS, Chicago, IL) was used for
statistical analysis. A P value <0.05 was considered statistically signiﬁcant.
results
patient characteristics
After review of records for >2500 patients who had died from
CRC, 264 patients with bone metastases who received
zoledronic acid (48%) or no bisphosphonate (12%; unknown
40%) therapy were identiﬁed. At the time of chart review, all
patients had died from their disease. Most patients had colon
cancer, and tumor histology was mostly nonmucinous
(Table 1).
characteristics of skeletal metastases
Bone metastases were primarily to the spinal column, with
vertebral involvement in 65% of patients. By comparison,
34% of patients had metastatic disease in the hip or pelvis,
26% had metastatic disease in the long bones, and 17% of
patients had osseous metastases in other sites (hands, feet,
and skull). Of the 264 patients, 114 (43%) had single bone
lesions during the course of the disease. Osteolytic lesions
were more prevalent than mixed lesions (81% versus 13% of
bone lesions, respectively), and mixed lesions were more
prevalent than osteoblastic lesions (6%). At the time of
diagnosis of bone lesions, the median intensity of pain
[visual analogue scale (VAS) score, 0–10] reported by
patients was 7.
clinical risk factors
The median time from primary CRC diagnosis to diagnosis
of bone metastases was 11.00 months [95% conﬁdence
interval (CI) 4.7–13.1 months; Table 2]. In a univariate
analysis exploring tumor site, tumor histology, tumor stage,
tumor grade, node status, and use of adjuvant
chemotherapy as risk factors, only tumor grade showed a
signiﬁcant correlation (P < 0.001) with the time to
developing bone metastases (Table 2).
The median time to ﬁrst SRE after the diagnosis of bone
metastases was 2.00 months (95% CI 1.04–3.45 months).
Radiation to bone was the predominant type of SRE, occurring
in approximately half of the patients (Figure 1). Pathologic
fracture was the second most common SRE, occurring in ∼10%
of patients. Spinal cord compression from metastatic disease
induced structural instability of the vertebrae and the
requirement for orthopedic surgery occurred at a similar
prevalence (6% each). Approximately one-third (32%) of
patients with bone metastases from colon cancer did not have
a reported SRE. Time to ﬁrst SRE was signiﬁcantly shorter for
patients with osteolytic lesions (1.00 month versus 2.00
months for osteoblastic, P < 0.001). However, the number of
bone metastases at presentation did not correlate with time to
ﬁrst SRE (P = 0.109) regardless of lesion type (i.e. osteolytic,
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osteoblastic, or mixed). Median survival after the ﬁrst SRE was
4.50 months (95% CI 2.8–5.7 months) in the overall study
population.
The median overall survival after diagnosis of bone
metastases was 7.00 months (95% CI 5.75–8.70 months). In
univariate analyses (Table 3), osteoblastic lesions (P = 0.008) or
the presence of only one bone lesion (P = 0.004) correlated
with longer median survival compared with osteolytic lesions
or the presence of two or more bone lesions. Neither the
occurrence of SREs (P = 0.88) nor use of zoledronic acid
(P = 0.161) signiﬁcantly correlated with survival after diagnosis
of bone metastases.
bisphosphonate therapy
Of the 264 patients with conﬁrmed bone metastases, 107 did
not have data on bisphosphonate use. These patients were
excluded, and a subgroup analysis was carried out on the
patients with well-documented bisphosphonate treatment
history. In this subset, 126 patients had received zoledronic
acid (4 mg every 4 weeks via 15-min i.v. infusion, with dose
adjustment based on creatinine clearance) and 31 patients had
not received an i.v. bisphosphonate.
Baseline demographics and disease characteristics were
generally similar between patients receiving zoledronic acid
and those not receiving zoledronic acid (Table 1). Patients who
received zoledronic acid had a signiﬁcantly longer time to ﬁrst
SRE than patients who did not receive zoledronic acid (2.00
months versus 1.00 month from diagnosis of bone metastasis,
respectively, P = 0.009) (Figure 2). Patients who received
zoledronic acid had a median overall survival of 10 months
(95% CI 8.09–11.91 months), which was a trend toward
improved survival, compared with patients who did not receive
zoledronic acid, in whom median survival was only 6.00
Table 1. Patient demographics and baseline disease characteristics
Characteristic Patients, n (%)
(N = 264)
No ZOLa
(N = 31)
ZOL
(N = 126)
Unknown
(N = 107)
Tumor site
Colon 163 (62) 21 (68) 78 (62) 62 (60)
Rectum 98 (37) 9 (29) 47 (37) 42 (39)
Unknown 3 (1) 1 (3) 1 (<1) 1 (<1)
Tumor histology
Nonmucinous 174 (66) 24 (77) 95 (75) 55 (51)
Mucinous 56 (21) 7 (23) 31 (25) 18 (17)
Unknown 34 (13) 0 0 34 (32)
Tumor grade
1 10 (4) 1 (3) 4 (3) 5 (5)
2 119 (45) 20 (65) 74 (59) 25 (23)
3 91 (34) 10 (32) 48 (38) 33 (31)
Unknown 44 (17) 0 0 44 (41)
Tumor stage
T1 5 (2) 0 0 5 (5)
T2 22 (8) 2 (6) 12 (10) 8 (7)
T3 153 (58) 17 (55) 64 (51) 72 (67)
T4 54 (20) NA NA NA
Unknown 30 (11) NA NA NA
Nodal status
N− 51 (19) 6 (19) 31 (25) 14 (13)
N+ 157 (59) 21 (68) 73 (58) 63 (59)
Unknown 56 (21) 4 (13) 22 (17) 30 (28)
Metastatic status
M0 104 (39) 12 (39) 50 (40) 42 (39)
M1 122 (46) 13 (42) 52 (41) 57 (53)
Unknown 38 (14) 6 (19) 24 (19) 8 (7)
Adjuvant chemotherapy
Yes 62 (23) 10 (32) 30 (24) 22 (21)
Stage II 4 (6) NA NA NA
Stage III 58 (94) NA NA NA
No 154 (58) 15 (48) 60 (48) 79 (74)
Unknown 48 (18) 6 (19) 36 (29) 6 (6)
Stage at diagnosis
Stage I 8 (3) 1 (3) 4 (3) 3 (3)
Stage II 31 (12) 4 (13) 15 (12) 12 (11)
Stage III 65 (25) 10 (32) 30 (24) 25 (23)
Stage IV 122 (46) 15 (48) 60 (48) 47 (44)
Unknown 38 (14) 1 (3) 17 (13) 20 (19)
Number of bone
metastases, nb
NA 35 145 NA
Location of lesion
Spine — 13 (37) 65 (45) —
Pelvis — 10 (29) 34 (23) —
Long bone — 7 (20) 32 (22) —
Other — 5 (14) 14 (10) —
Lesion type
Osteolytic — 28 (80) 116 (80) —
Osteoblastic — 3 (8) 12 (8) —
Mixed — 4 (12) 14 (10) —
Unknown — 0 3 (2) —
aPatients were known not to receive any bisphosphonate therapy.
bIncludes patients who had bone metastases at more than one site.
Percentages are based on total number of metastases not number of
patients.
Note that percentages may not total 100% because of rounding.
BP, bisphosphonate; N, node; NA, not available; ZOL, zoledronic acid.
Table 2. Median time from primary cancer diagnosis to diagnosis of bone
metastasis
Baseline characteristics Patients, n (%)
(N = 264)
Time,
months
95% CI P value
Tumor site
Rectum 163 (62) 12.00 6.8–17.2 0.336
Colon 98 (37) 11.00 8.75–13.25
Tumor histology
Nonmucinous 174 (66) 11.00 7.65–14.35 0.069
Mucinous 56 (21) 9.00 6.56–11.44
Tumor stagea
2 22 (8) 12.00 0–28.96 0.216
3–4 207 (78) 13.00 10.22–15.78
Tumor grade
1 10 (4) 33.00 9.76–56.24 <0.001
2 119 (45) 16.00 11.48–20.52
3 91 (34) 6.00 4.61–7.39
Nodal status
N− 51 (19) 20.00 13–27 0.138
N+ 157 (59) 13.00 10.48–15.52
Adjuvant chemotherapy
Yes 62 (23) 23.00 9.43–36.57 0.402
No 154 (58) 20.00 15.26–24.75
Overall 264 (100) 11.00 4.67–13.06
aAt initial diagnosis.
CI, conﬁdence interval; N, node.
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months (95% CI 4.46–7.54 months, P = 0.161). In multivariate
analyses, both osteolytic versus osteoblastic bone metastases
[hazard ratio (HR) = 4.92, 95% CI 1.75–13.78, P = 0.002] and
zoledronic acid versus no bisphosphonate therapy (HR = 0.73,
95% CI 0.48–0.99, P = 0.046) were independent factors that
correlated with longer time to ﬁrst SRE.
discussion
This retrospective study was the ﬁrst multicenter survey to
chronicle the natural history of bone metastasis in patients
with CRC. Approximately 10% of the >2500 CRC patients in
this analysis had bone metastases clearly documented in their
medical records. Because of the retrospective nature of the
review, only patients with at least one known bone metastasis
were evaluated, and some patients with poorly documented
bone metastases would not have been identiﬁed. Patients with
documented bone metastases, but who were alive at study
entry, were excluded. Therefore, the incidence of bone
metastases from CRC may be higher than the 10% of cases we
identiﬁed. Historically, the incidence of bone metastases from
CRC has been ∼6%, but a retrospective analysis (1993–2002)
of this patient population found that the rate has increased to
10.4%, likely due to improved survival and the prolonged time
patients are at risk for this complication [16]. The incidence of
bone metastases from CRC reported here is consistent with
this analysis. Furthermore, bone metastases were reported in
∼10% to 24%, based on clinical and autopsy records of
patients with advanced CRC (N = 118) [3]. In a more recent
retrospective analysis of positron emission tomography and/or
CT scans from 252 patients with colon cancer, 5.5% (n = 14) of
patients had bone metastases at primary diagnosis [4]. The
median time between primary diagnosis and diagnosis of bone
metastases was 21 months, and all patients with bone lesions
also had visceral metastases [4]. These data may reﬂect
improved early diagnosis of colon cancer in the last decade.
Colorectal cancers are relatively aggressive tumors, and the
current study revealed a median time to detection of bone
metastases in patients of 11.00 months. With current median
survival reports of >20 months for patients with metastatic
CRC [5–9, 19], it is likely that many patients may develop
bone metastases during the course of their disease and survive
for prolonged periods of time at risk for SREs. Better
understanding of the natural history may provide insight into
which patients should receive additional monitoring for
metastasis to bone to allow early treatment to prevent SREs.
For example, in the current analysis, tumor grade was found
to be predictive for the development of bone metastases
from CRC.
This evaluation of the natural history of bone metastasis
secondary to CRC suggests that there is a very aggressive
Figure 1. Incidence of skeletal-related events (SREs) occurring in patients with bone metastases from colorectal cancer (N = 264) egardless of therapy.
Table 3. Median survival after bone metastasis diagnosis
Variable Time, months 95% CI P valuea
Bone metastasis type
Osteolytic 7.00 5.87–8.13 0.008
Osteoblastic 21.00 5.90–36.11
Number of bone metastases
1 9.00 6.34–11.67 0.004
>1 6.00 4.9–7.1
SREs
No 7.00 5.43–8.57 0.88
Yes 7.00 5.58–8.43
Bisphosphonate treatment
ZOL 10.00 8.09–11.91 0.161
No ZOL 6.00 4.46–7.54
Overall 7.00 5.75–8.70
aLog-rank test.
CI, conﬁdence interval; SRE, skeletal-related event; ZOL, zoledronic acid.
Figure 2. Comparison of time to ﬁrst SRE in colorectal cancer patients
receiving zoledronic acid (n = 126) and those who did not receive
zoledronic acid (n = 31, P = 0.009). SE, standard error; SRE, skeletal-related
event; ZOL, zoledronic acid.
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disease course in bone that can result in potentially debilitating
SREs within a short time. According to the medical records,
the median time to developing the ﬁrst SRE after diagnosis of
bone metastases was only 1.00 month. Therefore, diagnosis of
bone metastases in a CRC patient should warrant immediate
attention and close follow-up. Patients with bone metastases
from CRC may have prolonged negative effects from
potentially disabling SREs, illustrated by the median survival
after development of bone metastases in our patients of 7.00
months and median survival after onset of ﬁrst SRE of 4.50
months. Unfortunately, patients’ function and quality of life
may be reduced by bone metastases and the associated SREs,
leading to increased requirements for supportive care, thus
creating a considerable burden for patients and the health care
system. Common complications from bone metastases in CRC
patients are similar to those reported in patients with bone
metastases from other solid tumors [11], and the most
commonly reported events included severe bone pain requiring
palliative radiotherapy to bone, pathologic bone fractures, and
spinal cord compression.
This retrospective analysis is consistent with the phase III
trials of zoledronic acid in patients with bone metastases from
solid tumors, including breast, lung, and prostate cancer
[20–22], and is the ﬁrst study to provide support for zoledronic
acid as an effective therapy for the prevention of SREs in
patients with bone metastases from CRC. In the current
analysis, the median time from diagnosis of bone metastases to
the ﬁrst SRE in patients who received zoledronic acid was
approximately double that of patients who received no i.v.
bisphosphonate therapy (2.00 months versus 1.00 month,
respectively, P = 0.009). Although the difference did not achieve
statistical signiﬁcance, patients with bone metastases from CRC
who received zoledronic acid showed a trend toward improved
overall survival versus patients who did not receive zoledronic
acid. Indeed, a population-based case-controlled analysis of
933 pairs of postmenopausal women (patients and controls)
showed that bisphosphonate use for treatment of
postmenopausal osteoporosis for >1 year was associated with a
signiﬁcant reduction in the relative risk for developing CRC
(relative risk = 0.50, 95% CI 0.35–0.71) [23]. Moreover,
potential progression-free or overall survival beneﬁts have been
reported with zoledronic acid in other advanced cancer settings
[24–30]. Some of these analyses suggest that the beneﬁts of
zoledronic acid could extend beyond SRE prevention and may
have anticancer potential.
Limitations of this study include its retrospective design and
missing information. Notably, the missing data may introduce
some bias into this trial. Data are missing for tumor stage
(12%), nodal status (21%), and metastases (14%). Moreover,
data regarding bisphosphonate use were not available for 40%
of patients.
Although there are guidelines for use of bisphosphonates in
patients with other speciﬁc tumors or solid tumors in general,
there is little guidance speciﬁc for patients with CRC [31–34].
This retrospective analysis of real-world data demonstrates that
bone metastases from CRC are typically aggressive and result
in the relatively rapid onset of SREs in the majority of patients.
Furthermore, the correlative analyses support the use of
zoledronic acid for the treatment of patients with bone
metastases from CRC to decrease the incidence of SREs and
possibly provide survival advantages.
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